Xeris Biopharma On Thursday Announced That The Fda Approved The Cortisol Synthesis Inhibitor Recorlev (Levoketoconazole) To Treat Endogenous Hypercortisolaemia In Adults With Cushing'S Syndrome For Whom Surgery Is Not An Option Or Has Not Been Curative. Ceo Paul Edick Said The Decision "Reinforces The Value That We Saw In Acquiring Strongbridge Biopharma'S Attractive Rare Disease Portfolio," A Deal Worth About $267 Million That Was Finalised In October.According To Xeris, The Filing Was Supported By Data From Two Phase Iii Trials That Evaluated A Combined Study Population Of 166 Patients That Is Representative Of The Adult Drug-Treated Us Population With Cushing'S Syndrome. Both The Sonics And Logics Trials Met Their Primary And Key Secondary Endpoints.Specifically, In The Sonics Study, Recorlev Demonstrated A Significant Normalisation Rate Of Urinary-Free Cortisol At Six Months Of Maintenance Therapy Without A Dose Increase. Meanwhile, Xeris Said Logics Confirmed The Efficacy And Safety Of Recorlev In Normalising And Maintaining Therapeutic Response Compared With Placebo."With This Approval, [Our]
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!